secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001396814-24-000057
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Pacira BioSciences director Gary Pace to retire June 30; consulting deal; shareholder votes
--------------------------------------------------------------------------------

- Director Gary Pace to retire from Board June 30, 2024; no disagreement with company.
- Consulting agreement amendment: one-year term from July 2024 to June 2025, $3,200/quarter for up to 8 hours.
- Shareholders elected Class I directors: Laura Brege, Mark Froimson, Mark Kronenfeld, Michael Yang.
- KPMG ratified as independent auditor for FY 2024 with ~43.9M for, 0.2M against.
- Advisory say-on-pay vote passed with ~37.2M for, 4.1M against, 2.7M broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681424000057/0001396814-24-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681424000057/pcrx-20240611.htm
  HTML page:      https://secwatch.observer/filing/0001396814-24-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer